Lisa Hui, Diana W. Bianchi
Index: 10.1146/annurev-med-072115-033220
Full Text: HTML
Noninvasive prenatal DNA testing is the vanguard of genomic medicine. In only four years, this screening test has revolutionized prenatal care globally and opened up new prospects for personalized medicine for the fetus. There are widespread implications for increasing the scope of human genetic variation that can be detected before birth, and for discovering more about maternofetal and placental biology. These include an urgent need to develop pretest education for all pregnant women and consistent post-test management recommendations for those with discordant test results. The reduction in invasive testing has had downstream effects on specialist training and caused many countries to re-examine their national approaches to prenatal screening. Finally, the accumulating datasets of genomic information on pregnant women and their fetuses raise ethical issues regarding consent for future data mining and intellectual property.
|
Gene Editing: A New Tool for Viral Disease
2017-01-18 [10.1146/annurev-med-051215-031129] |
|
The Type I Interferonopathies
2017-01-18 [10.1146/annurev-med-050715-104506] |
|
Esophageal Adenocarcinoma: Screening, Surveillance, and Mana...
2017-01-18 [10.1146/annurev-med-050715-104218] |
|
Management of Rectal Cancer Without Radical Resection
2017-01-18 [10.1146/annurev-med-062915-021419] |
|
The End of Nihilism: Systemic Therapy of Advanced Non–Small ...
2017-01-18 [10.1146/annurev-med-042915-102442] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2026 ChemSrc All Rights Reserved